The New Rules of Diagnostics: Lean Teams, Faster Revenue, Smarter Growth - MJ Hymes, i5 BioPartners

0:00-40:53

In this episode of Diagnosing Dx, I’m joined by MJ Hymes, Managing Partner at i5 BioPartners. MJ shares his journey from molecular biology into the commercial side of life sciences, and explains why great science alone is rarely enough to build a successful diagnostics or biotech company. We explore the gap between innovation and execution, why so many early-stage companies struggle to turn promising technology into real traction, and how the funding landscape has shifted for founders building today. We also discuss what it takes to get a life sciences company market-ready, from building leaner models earlier on to navigating commercialization, fundraising, and strategic support at the right time. From AI and multiomics to emerging technologies in diagnostics and drug discovery, this is a practical conversation about turning early-stage science into a real business.

Publisher

Diagnosing Dx

Link

podcasters.spotify.com/pod/show/medtech-disruptors2/episodes/The-New-Rules-of-Diagnostics-Lean-Teams--Faster-Revenue--Smarter-Growth---MJ-Hymes--i5-BioPartners-e3i9tno

Published

April 22, 2026

Duration

41 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

Elevra Consulting

DD

Diagnosing Dx

@diagnosingdx

#fasterrevenue #smartergrowth #i5biopartners #lifesciences

The Nile